Market Cap ₹1793 Cr.
Stock P/E 87.9
P/B 5.6
Current Price ₹172.3
Book Value ₹ 30.9
Face Value 1
52W High ₹1445.6
Dividend Yield 0.23%
52W Low ₹ 110
Bhagiradha Chemicals & Industries Ltd is engaged in agro chemicals enterprise. The Company manufactures agrochemical active constituents used as insecticides, fungicides and weedicides, which belong to the Crop Protection Chemical segment of the Agrochemical marketplace. Its pesticides include Chlorpyrifos, Chlorpyrifos-Methyl, Fipronil, Buprofezin, Thiamethoxam and Imidacloprid. The Company gives Azoxystrobin. Its herbicides consist of Imazethapyr, Clodinafop-propargyl and Cloquintocet-Mexyl. The Company also gives intermediates, along with (R)-(+)-2-(4-Hydroxyphenoxy) propionic acid. The Company's production unit is positioned near the eastern coastal city of Ongole, approximately 300km north of Chennai. The facility is supplied in about 14.7 hectares. It has an annual manufacturing capacity of about 3,200 tons. It exports its products to Australia, South Africa, China, Germany, Singapore, Spain, the United Kingdom, Belgium, Greece, Italy and Taiwan, amongst others.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 99 | 100 | 138 | 122 | 132 | 126 | 123 | 100 | 122 | 74 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Total Income | 100 | 100 | 138 | 122 | 132 | 126 | 123 | 100 | 122 | 75 |
| Total Expenditure | 83 | 84 | 117 | 102 | 112 | 107 | 104 | 93 | 109 | 66 |
| Operating Profit | 17 | 17 | 21 | 20 | 21 | 20 | 18 | 7 | 14 | 9 |
| Interest | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 12 | 12 | 16 | 16 | 17 | 16 | 14 | 3 | 9 | 5 |
| Provision for Tax | 3 | 4 | 6 | 4 | 5 | 5 | 5 | 1 | 3 | 1 |
| Profit After Tax | 8 | 9 | 11 | 12 | 12 | 12 | 9 | 2 | 6 | 3 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | 8 | 9 | 11 | 12 | 12 | 12 | 9 | 2 | 6 | 3 |
| Adjusted Earnings Per Share | 0.9 | 0.9 | 1.1 | 1.1 | 1.2 | 1.1 | 0.9 | 0.2 | 0.6 | 0.3 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|
| Net Sales | 246 | 318 | 436 | 502 | 419 |
| Other Income | 2 | 1 | 1 | 1 | 1 |
| Total Income | 247 | 319 | 437 | 503 | 420 |
| Total Expenditure | 229 | 271 | 367 | 425 | 372 |
| Operating Profit | 19 | 48 | 69 | 79 | 48 |
| Interest | 5 | 8 | 9 | 5 | 8 |
| Depreciation | 7 | 8 | 9 | 10 | 12 |
| Exceptional Income / Expenses | 2 | 1 | 0 | 0 | 0 |
| Profit Before Tax | 9 | 32 | 51 | 64 | 31 |
| Provision for Tax | 2 | 9 | 16 | 19 | 10 |
| Profit After Tax | 7 | 23 | 36 | 45 | 20 |
| Adjustments | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 7 | 23 | 36 | 45 | 20 |
| Adjusted Earnings Per Share | 0.7 | 2.5 | 3.8 | 4.3 | 2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 27% | 0% | 0% |
| Operating Profit CAGR | 14% | 61% | 0% | 0% |
| PAT CAGR | 25% | 86% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 23% | 58% | 33% | 51% |
| ROE Average | 18% | 18% | 15% | 15% |
| ROCE Average | 22% | 22% | 19% | 19% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Shareholder's Funds | 132 | 156 | 190 | 313 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 7 | 19 | 10 | 17 |
| Other Non-Current Liabilities | 1 | 3 | 9 | 16 |
| Total Current Liabilities | 83 | 95 | 133 | 101 |
| Total Liabilities | 224 | 273 | 342 | 447 |
| Fixed Assets | 138 | 152 | 157 | 173 |
| Other Non-Current Assets | 7 | 7 | 11 | 45 |
| Total Current Assets | 79 | 114 | 174 | 228 |
| Total Assets | 224 | 273 | 342 | 447 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 3 | 0 | 2 |
| Cash Flow from Operating Activities | 48 | 4 | 7 | 14 |
| Cash Flow from Investing Activities | -39 | -21 | -17 | -60 |
| Cash Flow from Financing Activities | -9 | 15 | 12 | 46 |
| Net Cash Inflow / Outflow | 0 | -2 | 2 | 1 |
| Closing Cash & Cash Equivalent | 3 | 0 | 2 | 3 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.69 | 2.46 | 3.77 | 4.34 |
| CEPS(Rs) | 1.39 | 3.32 | 4.69 | 5.28 |
| DPS(Rs) | 0 | 0 | 0.26 | 0.4 |
| Book NAV/Share(Rs) | 13.94 | 16.41 | 20.02 | 30.1 |
| Core EBITDA Margin(%) | 6.89 | 14.75 | 15.67 | 15.4 |
| EBIT Margin(%) | 5.86 | 12.71 | 13.86 | 13.7 |
| Pre Tax Margin(%) | 3.63 | 10.11 | 11.78 | 12.7 |
| PAT Margin (%) | 2.65 | 7.34 | 8.21 | 8.99 |
| Cash Profit Margin (%) | 5.36 | 9.9 | 10.21 | 10.95 |
| ROA(%) | 2.91 | 9.39 | 11.62 | 11.45 |
| ROE(%) | 4.92 | 16.2 | 20.69 | 17.95 |
| ROCE(%) | 8.26 | 20.6 | 24.75 | 21.72 |
| Receivable days | 17.07 | 40.85 | 65.45 | 81.91 |
| Inventory Days | 83.58 | 61.21 | 49.56 | 57.88 |
| Payable days | 56.11 | 64.76 | 67.37 | 66.76 |
| PER(x) | 32.07 | 17.99 | 23.6 | 27.58 |
| Price/Book(x) | 1.58 | 2.7 | 4.44 | 3.98 |
| Dividend Yield(%) | 0 | 0 | 0.3 | 0.33 |
| EV/Net Sales(x) | 1.01 | 1.51 | 2.11 | 2.57 |
| EV/Core EBITDA(x) | 13.29 | 10.12 | 13.32 | 16.43 |
| Net Sales Growth(%) | 0 | 29.4 | 37.05 | 15.25 |
| EBIT Growth(%) | 0 | 180.5 | 49.45 | 13.88 |
| PAT Growth(%) | 0 | 258.36 | 53.3 | 26.31 |
| EPS Growth(%) | 0 | 258.36 | 53.3 | 15.11 |
| Debt/Equity(x) | 0.32 | 0.4 | 0.42 | 0.16 |
| Current Ratio(x) | 0.95 | 1.2 | 1.31 | 2.27 |
| Quick Ratio(x) | 0.27 | 0.67 | 0.8 | 1.36 |
| Interest Cover(x) | 2.63 | 4.89 | 6.65 | 13.77 |
| Total Debt/Mcap(x) | 0.2 | 0.15 | 0.1 | 0.04 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 24.9 | 24.9 | 24.57 | 24.44 | 23.52 | 23.52 | 23.52 | 23.52 | 23.52 | 23.52 |
| FII | 1.08 | 0.89 | 0.43 | 0.2 | 0.1 | 0.1 | 0.12 | 0.1 | 0.17 | 0.16 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 74.02 | 74.21 | 75.01 | 75.36 | 76.38 | 76.38 | 76.36 | 76.38 | 76.31 | 76.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.21 | 0.21 | 0.26 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
| FII | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.62 | 0.62 | 0.78 | 0.78 | 0.79 | 0.79 | 0.79 | 0.79 | 0.79 | 0.79 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.83 | 0.83 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
